注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Zealand Pharma A/S 是一家总部位于丹麦的生物技术公司。该公司专注于发现、设计和开发用于代谢和胃肠道疾病以及其他未满足医疗需求的罕见疾病领域的肽类药物。该公司基于肽的候选产品包括临床开发、注册和潜在的商业化。其管道包括三个临床开发中的候选产品:格列帕鲁肽,正在开发用于治疗短肠综合征或短肠症候群;胰高血糖素配制用于双激素人工胰腺系统,以更好地管理糖尿病;和胰高血糖素用于治疗先天性高胰岛素血症。该公司在丹麦和美国开展业务,拥有一系列药物和候选产品,包括与勃林格殷格翰的合作。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Gudmund Tyge Korsgard | 67 | - | Board Observer |
Richard E. Pratley | - | 2011 | Member of Advisory Board |
Bernard Charbonnel | - | 2011 | Member of Advisory Board |
Gert Van Assche | - | 2011 | Member of Advisory Board |
Ake Lernmark | 79 | 2011 | Member of Advisory Board |
Paul Dorian | - | 2011 | Member of Advisory Board |
Bernadette Mary Connaughton | 66 | 2019 | Independent Director |
Kirsten Aarup Drejer | 68 | 2018 | Independent Vice Chairman |
Alf Gunnar Martin Nicklasson | 69 | 2014 | Independent Chairman of the Board |
Jeffrey Berkowitz | 58 | 2019 | Independent Director |
Leonard Kruimer | 66 | 2019 | Independent Director |
Cecilie Kold | - | - | Alternate Director |
Tanja Erichsen | - | 2024 | Alternate Director |
Anneline Nansen | 55 | 2021 | Employee Representative Director |
Lars Pedersen | - | 2024 | Alternate Director |
Enrique A. Conterno Martinelli | 58 | 2023 | Member of Advisory Board & Director |
Elaine Sullivan | 63 | 2023 | Director & Member of Advisory Board |
Ludovic Otterbein | - | 2024 | Employee Representative |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核